India, Jan. 16 -- PharmaCyte Biotech, a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box has announced PharmaCyte's partner, Austrianova, has successfully encapsulated the live cells used in PharmaCyte's therapy for its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). The cells are now growing and dividing inside the Cell-in-a-Box capsules.

PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, said, "We are now in the process of monitoring the growth and division of the live cells as they spend more time in a 'nutrient bath.' This will allow the cells to co...